Prevalence and clinical significance of HBeAg-positive chronic hepatitis B patients with and without anti-HBe antibody.

The clinical significance of the coexistence of hepatitis B e antigen (HBeAg) and antibodies against HBeAg (anti-HBe) in patients with chronic hepatitis B (CHB) remains unclear. This study investigated the clinical features and phase transition of patients with coexisting HBeAg/anti-HBe. A total of 840 treatment-naïve HBeAg-positive CHB patients from two medical centres were included.

Histological features of chronic hepatitis B patients with normal alanine aminotransferase according to different criteria.

Background: The upper limits of normal (ULNs) for alanine aminotransferase (ALT) are different among international guidelines for chronic hepatitis B (CHB). We aimed to investigate the proportion of significant histological disease in Asian patients with CHB with detectable hepatitis B virus (HBV) DNA under diverse ALT ULNs.

Methods: Consecutive patients with CHB and detectable HBV DNA who underwent liver biopsy were retrospectively included from four tertiary hospitals.

Noninvasive diagnosis of significant liver inflammation in patients with chronic hepatitis B in the indeterminate phase.

The presence of significant liver inflammation is an important indication for antiviral treatment in patients with chronic hepatitis B (CHB) in the indeterminate phase. We aimed to establish a non-invasive nomogram to predict significant liver inflammation in these patients. A total of 195 CHB patients in the indeterminate phase were randomly split into training and validation sets.

NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: A multi-center, retrospective study.

Introduction And Objectives: Chronic hepatitis B (CHB) may progress to more serious liver diseases and it is often accompanied by non-alcoholic fatty liver disease (NAFLD). NAFLD and CHB share risk factors for liver fibrosis and cirrhosis, but the influence of NAFLD on fibrosis progression is controversial. This retrospective study evaluated the prevalence of NAFLD in patients with CHB and investigated associations between NAFLD and liver fibrosis in a large multi-center cohort of hepatitis B patients submitted to liver biopsy.

Development and Validation of a Nomogram to Predict Significant Liver Inflammation in Patients with Chronic Hepatitis B.

Background: Noninvasive diagnosis of liver inflammation is important for patients with chronic hepatitis B (CHB). This study aimed to develop a nomogram to predict significant liver inflammation for CHB patients.

Methods: CHB patients who underwent liver biopsy were retrospectively collected and randomly divided into a development set and a validation set.

Significant histological disease of patients with chronic hepatitis B virus infection in the grey zone.

Background: Many patients with chronic hepatitis B (CHB) do not meet the definitions of the traditional natural phases and are classified as being in the grey zone (GZ).

Aims: To investigate liver histology, and to establish a management strategy for patients with CHB in the GZ.

Methods: This study included 1043 patients with CHB who underwent liver biopsy.

Clinical features of chronic hepatitis B patients with lean nonalcoholic fatty liver disease.

Background: The clinical features have been well described in obese chronic hepatitis B (CHB) patients with nonalcoholic fatty liver disease (NAFLD). However, little is known about the clinical features of lean CHB-NAFLD patients.

Methods: The study retrospectively included treatment-naïve CHB patients who underwent ultrasound between 2015 and 2021.

Presence of Liver Inflammation in Asian Patients With Chronic Hepatitis B With Normal ALT and Detectable HBV DNA in Absence of Liver Fibrosis.

Liver biopsies are recommended to exclude significant liver inflammation in patients with chronic hepatitis B (CHB) with elevated HBV DNA but without other indications for antiviral treatment. We aimed to investigate the proportions and determinants of significant inflammation in Asian patients with CHB with detectable HBV DNA. We conducted a cross-sectional study that retrospectively included 581 patients with CHB with detectable HBV DNA who had undergone liver biopsy.